pocketful logo
Neuland Laboratories Ltd logo

Neuland Laboratories Ltd

NSE: NEULANDLAB BSE: 524558

₹11995

(-0.88%)

Tue, 24 Mar 2026, 00:38 am

mtf coin illustrationMTF 5x

Neuland Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    14818.20

  • Net Profit

    260.11

  • P/B

    10.22

  • Sector P/E

    31.86

  • P/E

    59.90

  • EV/EBITDA

    36.84

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    20.07

  • ROCE (Industry)

    20.49

  • RONW (Industry)

    17.59

  • ROE

    14.84

  • ROCE

    18.58

  • Debt/Equity

    0.09

  • EPS (TTM)

    139.62

  • Dividend Yield

    0.10

  • Book Value

    1262.09

  • Interest Cover

    34.40

Analysis

all

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (10.5x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (15.9x coverage).
  • Cash flow for Neuland Laboratories is expected to increase by more than 50% in 2 years time.
  • Neuland Laboratories's earnings are expected to grow significantly at over 20% yearly.
  • Neuland Laboratories's earnings growth is expected to exceed the India market average.
thumbs up icon

Cons

  • Dividend payments have increased, but Neuland Laboratories only paid a dividend in the past 7 years.
  • Neuland Laboratories has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Neuland Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Neuland Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Neuland Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters32.6332.6432.6832.6832.68
FII20.9020.6021.6922.1123.86
DII14.7113.5411.5710.979.08
Public31.7632.8133.6733.8433.98
Government0.000.400.400.400.40

Read More

Technical Analysis

RSI

32.65

MACD

-393.28

50 DMA

13142.74

200 DMA

14345.87

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic16418.3314800.3313812.6713182.3312194.6711564.339946.33
Fibonacci14800.3314182.2613800.4113182.3312564.2612182.4111564.33
Camarilla13269.9513121.6312973.3213182.3312676.6812528.3712380.05

Pivots Level: Classic

R3

+3236.00

16418.33

R2

+1618

14800.33

R1

+630.33

13812.67

13182.33
13182.33
Pivot Point
LTP: 11555

S1

-987.67

12194.67

S2

-1618

11564.33

S3

-3236

9946.33

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    12223.12

  • 20-EMA

    12538.29

  • 30-EMA

    12790.05

  • 50-EMA

    13247.26

  • 100-EMA

    13893.58

  • 200-EMA

    13943.82

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
09 Feb 2026board-meetingsQuarterly Results
07 Nov 2025board-meetingsQuarterly Results
18 Jun 2025dividendFinal Dividend - Rs. - 1218 Jul 2025
15 May 2025dividend₹12.00 Dividend /Share18 Jul 2025
15 May 2025agm
12 Jun 2024dividendAnnual General Meeting/Dividend - Rs 14 Per Share13 Jul 2024
10 May 2024dividend₹14.00 Dividend /Share13 Jul 2024
10 May 2024agm
11 Jun 2023dividendAnnual General Meeting/Dividend - Rs 10 Per Share12 Jul 2023
11 May 2023agm

Read More

Peer Comparison

Neuland Laboratories Ltd logo

Neuland Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Neuland Laboratories Ltd About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1984

Headquarters

CEO

D Saharsh Rao

Employees

Contact

Website icon

Website

http://www.neulandlabs.com

Email icon

Email

ir@neulandlabs.com

Phone icon

Phone

91-40-30211600

Location icon

Location

11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035

Read More

Neuland Laboratories Ltd Company History

YearHistory
2012
  • Neuland Laboratories Ltd issued rights in the ratio of 5:12.
  • The registered office of the company was shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034.
2013
  • The board recommended a dividend of Rs. 1.20 per share of a face value of Rs. 10 each.
  • Neuland Labs received the 2013 CMO Leadership Award for Regulatory Excellence.
2014
  • Neuland Labs inaugurated a new manufacturing facility constructed for its collaboration with Mitsubishi Healthcare Unit API Corporation.
  • The board recommended a dividend of 30% at Rs. 3 per equity share on a face value of Rs. 10 each.
  • Neuland Laboratories announced rights in the ratio of 4:25.
2016
  • The company entered into a Joint Development Agreement with Phoenix Embassy Techno Zone Private Limited.
2017
  • Neuland Labs completed the acquisition of an API plant.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
SMALLCAP WORLD FUND INCSell48443415618.1612 Dec 2024
SMALLCAP WORLD FUND INCBuy130000740026 Jun 2024
MALABAR INDIA FUND LIMITEDSell130000740026 Jun 2024
RAMAMOHAN RAO DAVULURISell4000005012.4508 Dec 2023
BNP PARIBAS ARBITRAGESell648933871.3131 Aug 2023
BNP PARIBAS ARBITRAGEBuy708972898.3815 May 2023
GRAVITON RESEARCH CAPITAL LLPBuy739212858.7615 May 2023
GRAVITON RESEARCH CAPITAL LLPSell739212861.5215 May 2023
NK SECURITIES RESEARCH PRIVATE LIMITEDSell659272493.3411 May 2023
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy658272491.9911 May 2023

Read More

Neuland Laboratories Ltd News

Neuland Labs Issues Share Certificate Confirmation

Neuland Laboratories Limited issued Letter of Confirmation for 100 lost shares to shareholder Rajesh Khandwala under SEBI regulations, informing BSE and NSE exchanges.

19 Mar 2026

companies

Neuland Labs Director Dr. Christopher Cimarusti Passes Away

Neuland Laboratories announces the sad demise of Dr. Christopher M Cimarusti, Non-Executive Non-Independent Director, who passed away on February 28, 2026. He served on the board since 2009.

03 Mar 2026

stocks

Neuland Labs Q3FY26 Results Show Mixed Performance

Neuland Laboratories reports 11.4% revenue growth to Rs. 447.8 crore in Q3FY26, but EBITDA margins decline 350 bps to 19.0% amid product mix challenges and higher operating expenses.

09 Feb 2026

co actions results

Neuland Labs Board Meet Set for Feb 9 to Review Q3 Results

Neuland Laboratories has scheduled a board meeting on February 9, 2026, to approve Q3FY26 unaudited financial results. Trading window remains closed until 48 hours post-declaration.

21 Jan 2026

co actions results

Neuland Labs Exports Surge 143% MoM to $20.4M

Neuland Laboratories reported a significant 143% month-on-month increase in exports, reaching $20.4 million, demonstrating strong international business growth and operational momentum.

13 Jan 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800